This graphic shows the big picture of AIDS vaccine concepts and clinical trials in process and on the horizon. It is an internationally simplified representation of a complex field. Some approaches are not listed, and related arenas like and cure research are omitted.
Vaccine Research: An overview
Additional Vaccine Approaches
A range of vaccine approaches are being tested in early phase clinical trials. This table provides highlights of this area of vaccine research.
Neutralizing Antibodies
This graphic explains on how neutralizing antibodies work, provides research background and gives an advocates’ checklist for what to look for going forward.
Vaccine Research Developing Programs
This graphic provides a state of the field on vaccine research development programs, giving details on the Pox-Protein Public-Private Partnership trials testing canarypox-protein based vaccine candidates and the Jannssen development program of Ad26 vector + Mosaic immunogen vaccine strategy.
Selected Guide to Pipeline of Antibodies, Long-Acting ARVs and Vaccines
This graphic provides a quick primer on passive immunization with HIV-specific antibodies, long-acting antiretroviral injectables, and preventive vaccines, including a new, informative table reviewing the pipelines in research and development for all three research avenues.
What’s Next for the Pox-Protein Public-Private Partnership (P5)?
This timeline, appearing in AVAC Report 2014/2015: HIV Prevention on the Line, shows the progress and future of the P5.
Turning Targets into Impact
This graphic, which appears in the AVAC Report 2014/15, lists and describes key attributes that ensure a target into impact.
Mind the Gap
This graphic, presented in the AVAC Report 2014/15: HIV Prevention on the Line, shows all the components of a comprehensive response to end the epidemic.
Targets that Worked
As seen in this graphic from AVAC Report 2014/15: HIV Prevention on the Line, ambitious coverage targets that are well-defined in terms of the components of service delivery, impact and populations and need led to success for VMMC (VMMC) and antiretroviral therapy (ART).
A Target That Worked: 3 by 5
Appearing in AVAC Report 2014/2015: HIV Prevention on the Line, this graphic shows how a target was set and met to provide ART Treatment U=U to 3 million people.